U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H24N2O4S2.2ClH
Molecular Weight 397.382
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BICISATE DIHYDROCHLORIDE

SMILES

Cl.Cl.CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC

InChI

InChIKey=HKASNZKRIQURIX-BZDVOYDHSA-N
InChI=1S/C12H24N2O4S2.2ClH/c1-3-17-11(15)9(7-19)13-5-6-14-10(8-20)12(16)18-4-2;;/h9-10,13-14,19-20H,3-8H2,1-2H3;2*1H/t9-,10-;;/m0../s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C12H24N2O4S2
Molecular Weight 324.46
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Bicisate hydrochloride is a ligand that is used to form a complex with technetium. Tc99m Bicisate forms a stable, lipophilic complex that crosses intact cell membranes and blood brain barrier by passive diffusion. The amount of tc99m bicisate is stable in the brain until about 6 hours. Tc99m bicisate is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed.

CNS Activity

Curator's Comment: Tc99m Bicisate forms a stable, lipophilic complex that crosses intact cell membranes and blood brain barrier by passive diffusion

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
NEUROLITE

Approved Use

Tc99m bicisate is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed

Launch Date

1994
PubMed

PubMed

TitleDatePubMed
Brain SPECT imaging and psychiatry.
1992 Nov
99mTc-bicisate reliably images CBF in chronic brain diseases but fails to show reflow hyperemia in subacute stroke: report of a multicenter trial of 105 cases comparing 133Xe and 99mTc-bicisate (ECD, neurolite) measured by SPECT on same day.
1994 Jan
Patents

Sample Use Guides

In Vivo Use Guide
This drug is administered by intravenous injection for diagnostic use after reconstitution with sterile, non-pyrogenic, oxidant-free Sodium Pertechnetate Tc99m Injection.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:33:47 GMT 2023
Edited
by admin
on Fri Dec 15 15:33:47 GMT 2023
Record UNII
B005P07V07
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BICISATE DIHYDROCHLORIDE
Common Name English
Bicisate dihydrochloride [WHO-DD]
Common Name English
L-CYSTEINE, N,N'-1,2-ETHANEDIYLBIS-, DIETHYL ESTER, DIHYDROCHLORIDE
Common Name English
CYSTEINE, N,N'-ETHYLENEDI-, DIETHYL ESTER, DIHYDROCHLORIDE, L-
Common Name English
L-CYSTEINE, N,N'-1,2-ETHANEDIYLBIS-, 1,1'-DIETHYL ESTER, HYDROCHLORIDE (1:2)
Common Name English
DIETHYL (2R,2'R)-2,2'-(ETHANE-1,2-DIYLDIIMINO)BIS(3-MERCAPTOPROPANOATE) DIHYDROCHLORIDE
Systematic Name English
Code System Code Type Description
PUBCHEM
71586979
Created by admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
PRIMARY
RXCUI
1306099
Created by admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
PRIMARY RxNorm
EVMPD
SUB119911
Created by admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
PRIMARY
DRUG BANK
DBSALT001533
Created by admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID4046656
Created by admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
PRIMARY
DAILYMED
B005P07V07
Created by admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
PRIMARY
SMS_ID
100000143314
Created by admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
PRIMARY
CAS
14344-58-2
Created by admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
PRIMARY
FDA UNII
B005P07V07
Created by admin on Fri Dec 15 15:33:47 GMT 2023 , Edited by admin on Fri Dec 15 15:33:47 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY